爾康製藥(300267.SZ):擬續聘天健會計師事務所
格隆匯11月19日丨爾康製藥(300267.SZ)公佈,公司於2021年11月19日召開了第四屆董事會第十八次會議和第四屆監事會第十八次會議,會議審議通過了《關於續聘2021年度審計機構的議案》,公司擬續聘天健會計師事務所(特殊普通合夥)為公司2021年度審計機構,並提交公司2021年第二次臨時股東大會審議。
天健會計師事務所(特殊普通合夥)具備證券、期貨相關業務審計從業資格,具有上市公司審計工作的豐富經驗和職業素養,能夠較好滿足公司建立健全內部控制以及財務審計工作的要求。其在擔任公司審計機構期間,勤勉盡責,能夠遵循《中國註冊會計師獨立審計準則》等相關規定,堅持獨立、客觀、公正的審計準則,公允合理地發表審計意見。
為保持審計工作的連續性,公司董事會同意續聘天健會計師事務所(特殊普通合夥)為公司2021年度審計機構,聘期一年,自公司股東大會審議通過之日起生效。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.